Definition and pharmacological rationale
Bempedoic acid is an oral, small-molecule lipid-lowering agent used to reduce low-density lipoprotein cholesterol (LDL-C), particularly when statins cannot be tolerated or when LDL-C remains above goal despite maximally tolerated therapy.
It is a prodrug activated predominantly in the liver by very long-chain acyl-CoA synthetase-1. This activating enzyme is not expressed in skeletal muscle, a pharmacological feature that may limit muscle-related toxicity despite bempedoic acid acting within the same broad cholesterol-synthesis pathway as statins.
The principal molecular target is adenosine triphosphate citrate lyase (ACL), a cytosolic enzyme upstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase in the cholesterol-synthesis pathway. Inhibition of ACL reduces hepatic cholesterol synthesis and produces reductions in LDL-C, non-high-density lipoprotein cholesterol, apolipoprotein B and high-sensitivity C-reactive protein (hsCRP).
Bempedoic acid also activates adenosine monophosphate-activated protein kinase, which regulates substrates involved in lipid metabolism and inflammatory signalling. ACLY additionally influences fatty-acid synthesis and may affect epigenetic regulation through changes in DNA acetylation.
Lipid-lowering efficacy
Bempedoic acid is available as a single daily dose of 180 mg. The LDL-C response varies with background therapy:
| Treatment setting | Approximate LDL-C reduction versus placebo |
|---|---|
| Monotherapy | 23% |
| Added to background statin therapy | 18% |
| Fixed-dose combination with ezetimibe | 38% |
| Pooled analyses across different background therapies | 17%–25% |
In patients with atherosclerotic vascular disease or familial hypercholesterolaemia, addition of bempedoic acid to statin therapy reduced LDL-C by approximately 16.5%; the reduction in a subgroup with diabetes was approximately 19.1%.
The drug also lowers hsCRP. In a population of individuals unable or unwilling to take statins, bempedoic acid 180 mg daily produced approximately 21% reductions in both LDL-C and hsCRP. Individual responses vary, making biochemical reassessment after treatment initiation or intensification necessary.
Clinical evidence for cardiovascular benefit
CLEAR Outcomes
CLEAR Outcomes was a randomized, double-blind, placebo-controlled study of 13,970 patients at high cardiovascular risk who were unable or unwilling to take statins. Approximately 70% were in secondary prevention and 30% in primary prevention; 23% were taking a small dose of a statin, defined as atorvastatin less than 10 mg daily or an equivalent dose of another statin. Approximately 45% of participants had type 2 diabetes.
Over a median follow-up of 40.6 months, the time-averaged LDL-C difference between bempedoic acid and placebo was 0.57 mmol/L (22 mg/dL). The composite major adverse cardiovascular outcome—cardiovascular death, nonfatal myocardial infarction, nonfatal stroke or coronary revascularization—occurred in 819 patients receiving bempedoic acid (11.7%) and 927 receiving placebo (13.3%).
Bempedoic acid reduced this composite outcome by approximately 13%:
Hazard ratio: 0.87
95% confidence interval: 0.79–0.96
P = .004
Other summaries of the trial describe a 14% reduction in the same composite outcome. There was no apparent reduction in cardiovascular death considered separately:
Hazard ratio for cardiovascular death: 1.04
95% confidence interval: 0.88–1.24
The magnitude of cardiovascular risk reduction was considered similar to that achieved with statins for a comparable absolute degree of LDL-C lowering.
Diabetes and glycaemic outcomes
Among participants with diabetes, bempedoic acid produced significant relative and absolute reductions in four-component major adverse cardiovascular events. The reported hazard ratio was 0.83, with a 95% confidence interval of 0.72–0.95 and an absolute risk reduction of 2.4%. There was no statistical evidence that glycaemic status modified the treatment effect.
Across the available evidence, bempedoic acid did not increase new-onset diabetes or worsen haemoglobin A1c. In CLEAR Outcomes, new-onset diabetes and hyperglycaemia occurred less often with bempedoic acid than with placebo. The absence of an adverse effect on haemoglobin A1c was also observed in individuals with normoglycaemia or prediabetes.
Clinical use
Appropriate clinical setting
The principal role of bempedoic acid is LDL-C lowering in patients who:
Are unable to take statin therapy because of adverse effects or intolerance.
Require additional LDL-C reduction despite the maximally tolerated statin dose.
Remain above the LDL-C goal despite statin therapy with or without ezetimibe.
May benefit from an oral non-statin option with demonstrated cardiovascular outcome benefit.
Bempedoic acid may be used alone or combined with other lipid-lowering agents. The fixed-dose combination with ezetimibe provides greater LDL-C lowering than either agent alone, although the combination itself has not been tested in outcomes trials according to the source material.
The choice of non-statin therapy should reflect:
The additional LDL-C reduction required.
Patient preference.
Treatment availability.
Cost.
The degree of statin tolerance and the background regimen.
For patients with a history of muscle symptoms, the evidence supports consideration of a maximally tolerated statin dose where possible, with addition of a non-statin agent when LDL-C goals are not achieved. Alternate-day low-intensity statin therapy is described as potentially effective in some patients with previous muscle problems.
Dosing
The available single dose is:
- Bempedoic acid 180 mg orally once daily
A fixed-dose combination with ezetimibe is also approved by the U.S. Food and Drug Administration and the European Medicines Agency, although the source material does not provide its component doses.
Safety and adverse effects
Musculoskeletal effects
Because activation is concentrated in the liver and the activating enzyme is not expressed in skeletal muscle, bempedoic acid has limited muscle-related effects. Across clinical studies, the rate of myalgia was comparable to placebo, and muscle-related adverse events were similar to those observed with placebo.
This profile makes bempedoic acid particularly relevant when muscle symptoms limit statin treatment.
Uric acid and gout
Bempedoic acid causes a small, reversible increase in uric acid. In CLEAR Outcomes, hyperuricaemia occurred in 10.9% of patients receiving bempedoic acid compared with 5.6% receiving placebo. Gout occurred in 3.1% and 2.1%, respectively.
A history of gout is not an absolute contraindication, but caution is warranted. Patients with previous gout require clinical assessment of the potential risk and appropriate monitoring for recurrent symptoms.
Renal findings
Mild, reversible increases in blood urea nitrogen and creatinine have been observed. In CLEAR Outcomes, renal impairment was reported in 11.5% of patients receiving bempedoic acid compared with 8.6% receiving placebo.
Hepatic enzymes
Elevation of hepatic enzymes was more frequent with bempedoic acid. Elevation of alanine aminotransferase or aspartate aminotransferase to more than twice the upper limit of normal occurred in 4.5% of treated patients compared with 3.0% of those receiving placebo.
Other adverse findings
The following events were reported more frequently with bempedoic acid than placebo in CLEAR Outcomes:
| Adverse finding | Bempedoic acid | Placebo |
|---|---|---|
| Cholelithiasis | 2.2% | 1.2% |
| Increased platelet count | 7.2% | 0.8% |
| Decreased haematocrit | 2.3% | 0.1% |
These findings support attention to uric acid, renal indices, hepatic enzymes and blood counts when clinically indicated, particularly in patients with relevant comorbidities or symptoms. The source material does not specify a formal laboratory-monitoring schedule beyond reassessment of LDL-C after treatment changes.
Laboratory assessment and follow-up
LDL-C should be measured 4–6 weeks after initiating or intensifying lipid-lowering treatment. This interval permits assessment of treatment response and helps determine whether the LDL-C goal has been reached.
Because inter-individual variability in LDL-C reduction is substantial, treatment should not be judged solely from expected average efficacy. Follow-up should incorporate:
LDL-C response.
Adherence and tolerability.
The need for additional LDL-C lowering.
Symptoms suggestive of gout or cholelithiasis.
Hepatic, renal, uric-acid or haematological abnormalities when clinically appropriate.
The source material does not provide specific targets for LDL-C, uric acid, creatinine, transaminases or haematocrit, nor does it define dose-adjustment protocols for abnormal results.
Guideline recommendations
The European guideline recommendations include the following:
| Recommendation | Class | Level of evidence |
|---|---|---|
| Non-statin therapies with proven cardiovascular benefit, used alone or in combination, are recommended in patients unable to take statins to lower LDL-C and reduce cardiovascular events. Choice should reflect the amount of additional LDL-C lowering needed. | I | A |
| Bempedoic acid is recommended for patients unable to take statins who require treatment to achieve the LDL-C goal. | I | B |
| Addition of bempedoic acid to the maximally tolerated statin dose, with or without ezetimibe, should be considered in patients at high or very high cardiovascular risk who have not reached the LDL-C goal. | IIa | C |
The guideline framework places bempedoic acid alongside ezetimibe and PCSK9 monoclonal antibodies as non-statin therapies with demonstrated cardiovascular benefit. Therapy may be used alone or in combination, according to the degree of residual LDL-C elevation and the clinical circumstances.
In patients with diabetes, bempedoic acid has evidence of cardiovascular benefit without worsening haemoglobin A1c or increasing new-onset diabetes. In patients with peripheral arterial disease, it has been associated with reduced major adverse cardiovascular events, although its effect on aortic disease and abdominal aortic aneurysm requires further research.
Practical prescribing considerations
Bempedoic acid is particularly attractive when statin therapy is not possible because:
It is administered orally once daily.
Its activating enzyme is not expressed in skeletal muscle.
Muscle-related adverse events are similar to placebo.
It has demonstrated cardiovascular outcome benefit in statin-intolerant, high-risk patients.
It does not appear to worsen glycaemic control.
It can be combined with ezetimibe or added to a maximally tolerated statin regimen.
The principal cautions relate to:
Previous gout or hyperuricaemia.
Renal impairment or a tendency toward renal laboratory abnormalities.
Hepatic enzyme elevation.
Symptoms or history suggestive of gallstone disease.
Changes in platelet count or haematocrit when clinically relevant.
Although gout does not constitute an absolute contraindication, the potential for uric-acid elevation should be incorporated into shared treatment decisions.
Prognosis and longer-term management
Bempedoic acid improves cardiovascular outcomes in high-risk patients unable or unwilling to take statins, with the clearest evidence relating to the composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and coronary revascularization. The trial evidence did not demonstrate a significant reduction in cardiovascular death considered separately.
Long-term management should therefore remain risk-based and should not regard bempedoic acid as a substitute for comprehensive cardiovascular prevention. Its role is to achieve adequate LDL-C lowering, either as monotherapy in statin-intolerant patients or in combination with tolerated statin and other non-statin therapies.
The durability of treatment should be reassessed through periodic review of:
LDL-C and attainment of the therapeutic goal.
Tolerability and adherence.
Gout, hyperuricaemia and other adverse effects.
The continuing need for combination therapy.
Patient preferences, treatment access and cost.
The available source material reports follow-up through 40.6 months in CLEAR Outcomes. It does not provide longer-term outcome data, specific surveillance intervals beyond the 4–6-week lipid reassessment, or detailed management pathways for individual laboratory abnormalities.
